Online inquiry

IVTScrip™ mRNA-Anti-CGRP, ALD-403(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2130MR)

This product GTTS-WQ2130MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CALCA&CALCB gene. The antibody can be applied in Migraine research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001033952.3; NM_000728.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 796; 797
UniProt ID P01258; P10092
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CGRP, ALD-403(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ2130MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14559MR IVTScrip™ mRNA-Anti-CD19, aCD1919(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA aCD1919
GTTS-WQ4751MR IVTScrip™ mRNA-Anti-SOST, BPS-804(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BPS-804
GTTS-WQ4811MR IVTScrip™ mRNA-Anti-CD4, BT-061(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BT-061
GTTS-WQ4189MR IVTScrip™ mRNA-Anti-IL2RA, BIIB019(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BIIB019
GTTS-WQ257MR IVTScrip™ mRNA-Anti-EPCAM, 17-1A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 17-1A
GTTS-WQ3458MR IVTScrip™ mRNA-Anti-S, AZD8895(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AZD8895
GTTS-WQ4608MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-986015
GTTS-WQ5841MR IVTScrip™ mRNA-Anti-CD3E, ChAglyCD(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ChAglyCD
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW